Artykuły w czasopismach na temat „Gcb-Dlbcl”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Sprawdź 50 najlepszych artykułów w czasopismach naukowych na temat „Gcb-Dlbcl”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Przeglądaj artykuły w czasopismach z różnych dziedzin i twórz odpowiednie bibliografie.
Pukiat, Sulada, Nuttapong Ngamphaiboon, Pooja Advani, Julio Chavez, George Deeb, Anjana Elefante i Francisco J. Hernandez-Ilizaliturri. "BCL-2 Expression at the Time of Diagnosis Affects the Clinical Outcome of Patients with Germinal Center and Non-Germinal Center Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Chemo-Immunotherpy". Blood 116, nr 21 (19.11.2010): 3130. http://dx.doi.org/10.1182/blood.v116.21.3130.3130.
Pełny tekst źródłaTarius, Jenifer Marsela, Hermawan Istiadi, Ika Pawitra Miranti i Intan Rahmania Eka Dini. "THE CORRELATION BETWEEN CELL OF ORIGIN SUBTYPE WITH OVERALL SURVIVAL OF DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS IN KARIADI GENERAL HOSPITAL SEMARANG". DIPONEGORO MEDICAL JOURNAL (JURNAL KEDOKTERAN DIPONEGORO) 9, nr 3 (12.05.2020): 252–58. http://dx.doi.org/10.14710/dmj.v9i3.27504.
Pełny tekst źródłaGandhi, Shipra, Vishala T. Neppalli, George Deeb, Myron S. Czuczman i Francisco J. Hernandez-Ilizaliturri. "Distinct CD30 Expression Patterns In Germinal Center B-Cell (GCB) and Non-GCB Diffuse Large B-Cell Lymphoma (DLBCL)". Blood 122, nr 21 (15.11.2013): 5064. http://dx.doi.org/10.1182/blood.v122.21.5064.5064.
Pełny tekst źródłaHayama, Miyuki, Masataka Okamoto, Yuki Hagiwara, Ken Tanae, Mika Kohri, Naoki Takahashi, Tadashi Yoshino, Koichi Ohshima i Nozomi Niitsu. "Clinical Significance of Immunohistochemical Markers of Diffuse Large B-Cell Lymphoma In the Rituximab Era." Blood 116, nr 21 (19.11.2010): 1800. http://dx.doi.org/10.1182/blood.v116.21.1800.1800.
Pełny tekst źródłaKharchenko, Yevgeniya, Tatyana Semiglazova, Anna Artemeva, Galina Kireeva, I. Polyatskin, Ilya Zyuzgin, Larisa Filatova, Yuliya Chudinovskikh, Margarita Motalkina i Yuliya Oleynik. "PROGNOSTIC IMPACT OF IMMUNOHISTOCHEMICAL AND MOLECULAR GENETIC MARKERS IN DIFFUSE LARGE B-CELL LYMPHOMA". Problems in oncology 66, nr 1 (1.01.2020): 79–89. http://dx.doi.org/10.37469/0507-3758-2020-66-1-79-89.
Pełny tekst źródłaAdhi Pangarsa, Eko, Desta Nur Ewika Ardini, Daniel Rizky, Kevin Tandarto, Hermawan Istiadi, Dik Puspasari, Budi Setiawan i in. "The association of Hypoxia-Inducible Factor-2α (HIF-2α) overexpression score with Germinal Center B-Cell Like (GCB) and Non-Germinal Center B-Cell Like (Non-GCB) subtypes of Diffuse Large B-cell Lymphoma (DLBCL)". Bali Medical Journal 12, nr 3 (22.08.2023): 2456–62. http://dx.doi.org/10.15562/bmj.v12i3.4521.
Pełny tekst źródłaMishima, Yuko, Masahiro Yokoyama, Noriko Nishimura, Kyoko Ueda, Tadahiro Gunji, Hideaki Nitta, Yoshiharu Kusano i in. "R-CHOP Therapy Cannot Overcome CD5 Positive Non-GCB Subtype of DLBCL". Blood 126, nr 23 (3.12.2015): 1507. http://dx.doi.org/10.1182/blood.v126.23.1507.1507.
Pełny tekst źródłaChavez, Julio, Mark Walsh, Francisco J. Hernandez-Ilizaliturri, Anjana Elefante i Myron S. Czuczman. "Classification of Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) According to the Han's Criteria Defines Two Groups of Patients with Different Clinical Outcomes Following Systemic Rituximab-Multi Agent Anthracycline-Based Therapy." Blood 114, nr 22 (20.11.2009): 623. http://dx.doi.org/10.1182/blood.v114.22.623.623.
Pełny tekst źródłaVan Meerten, Tom, Renee Bouwstra, Yuan He, de Boer Janneke, Hilde Kooistra, Rudolf Fehrmann, Emanuele Ammatuna, Gerwin Huls i Edwin Bremer. "CD47 Expression Defines the Efficacy of Rituximab in Non-Germinal Center B-Cell (non-GCB) Diffuse Large B-Cell Lymphoma (DLBCL)". Blood 132, Supplement 1 (29.11.2018): 2852. http://dx.doi.org/10.1182/blood-2018-99-114561.
Pełny tekst źródłaNiitsu, Nozomi, Naoki Takahashi, Tadashi Yoshino, Masataka Okamoto i Shigeo Nakamura. "Prognostic Significance of EBV Association in Diffuse Large B-Cell Lymphoma in the Rituximab Era". Blood 126, nr 23 (3.12.2015): 3911. http://dx.doi.org/10.1182/blood.v126.23.3911.3911.
Pełny tekst źródłaAlam, SM Mahbubul, i Ahmed Khaled. "Immunophenotypic characteristics of Diffuse Large Bcell Lymphoma". Bioresearch Communications 8, nr 1 (26.12.2021): 1049–52. http://dx.doi.org/10.3329/brc.v8i1.57043.
Pełny tekst źródłaNooruddin, Zohra, Zenggang Pan, Lilyana Gross, Weitzenkamp David, Bradley M. Haverkos, Daniel A. Pollyea, Jonathan A. Gutman i in. "Post-Transplant Diffuse Large B Cell Lymphoma with Non Germinal Center B-Cell Subtype Frequently Lacks Programmed Cell Death Ligand (PD-L1) Overexpression Which May Influence Overall Outcomes". Blood 128, nr 22 (2.12.2016): 3054. http://dx.doi.org/10.1182/blood.v128.22.3054.3054.
Pełny tekst źródłaSlimani, Yasmine, Fouzia Hali i Fatima-Zohra El Fatoiki. "Triple-negative diffuse large B-cell lymphoma: A distinct entity". Our Dermatology Online 12, nr 4 (19.10.2021): 427–29. http://dx.doi.org/10.7241/ourd.20214.17.
Pełny tekst źródłaLossos, Izidore S., XiaoQing Lu, Feiying Ding, Manuel Rosado, Ash A. Alizadeh i Hovav Nechushtan. "Distinct IL-4 Intracellular Signaling in Germinal Center B-Cell like and Activated B-Cell like Diffuse Large B-Cell Lymphoma: Novel Opportunities for Therapeutic Interventions." Blood 104, nr 11 (16.11.2004): 244. http://dx.doi.org/10.1182/blood.v104.11.244.244.
Pełny tekst źródłaCosta, Luciano J., Andrew L. Feldman, Ivana N. Micallef, David J. Inward, Patrick B. Johnston, Luis F. Porrata, Mark R. Litzow i Stephen M. Ansell. "Germinal Center B Cell and Non-Germinal Center B Cell-Like DLBCL Have Similar Clinical Features at the Time of Progression and Comparable Outcome Following Autologous HSC Transplantation." Blood 110, nr 11 (16.11.2007): 1901. http://dx.doi.org/10.1182/blood.v110.11.1901.1901.
Pełny tekst źródłaJulianty, Patricia Fransisca, Maria Francisca Ham, Kusmardi Kusmardi i Agnes Stephanie Harahap. "CD30 Expression in Germinal Center B-cell-like and non-Germinal Center B-cell-like Subtypes of Diffuse Large B-cell Lymphoma". Open Access Macedonian Journal of Medical Sciences 8, B (17.04.2020): 375–80. http://dx.doi.org/10.3889/oamjms.2020.4645.
Pełny tekst źródłaLenz, Georg, George Wright, Sandeep Dave, Alexander Kohlmann, Wenming Xiao, John Powell, Hong Zhao i in. "Gene Expression Signatures Predict Overall Survial in Diffuse Large B Cell Lymphoma Treated with Rituximab and Chop-Like Chemotherapy." Blood 110, nr 11 (16.11.2007): 348. http://dx.doi.org/10.1182/blood.v110.11.348.348.
Pełny tekst źródłaNechushtan, Hovav, Joseph D. Rosenblatt i Izidore S. Lossos. "IL-4 Affects Proliferation, Chemosensitivity-and Rituximab Sensitivity of Germinal Center B-Cell like (GCB) and Activated B-Cell like (ABC) Diffuse Large B-Cell Lymphoma Differently." Blood 104, nr 11 (16.11.2004): 242. http://dx.doi.org/10.1182/blood.v104.11.242.242.
Pełny tekst źródłaLocatelli, Silvia L., Roberto Papait, Giuseppa Careddu, Ada Koschorke, Giuliano G. Stirparo, Monica Balzarotti, Luca Castagna, Armando Santoro i Carmelo Carlo-Stella. "Upregulation of Cereblon Expression By the DNA Methyltransferase Inhibitor Azacytidine Strongly Enhances Lenalidomide Cytotoxicity in Germinal Center B-Cell-like (GCB) and Activated B-Cell-like (ABC) Diffuse Large B-Cell Lymphoma (DLBCL)". Blood 124, nr 21 (6.12.2014): 2253. http://dx.doi.org/10.1182/blood.v124.21.2253.2253.
Pełny tekst źródłaKleinstern, Geffen, Dennis P. Robinson, Lisa M. Rimsza, Melissa C. Larson, Rebecca L. King, Grzegorz S. Nowakowski, Carrie A. Thompson i in. "Abstract 741: Evaluation of etiologic heterogeneity for risk of diffuse large B-cell lymphoma (DLBCL) subtype defined by cell-of-origin". Cancer Research 82, nr 12_Supplement (15.06.2022): 741. http://dx.doi.org/10.1158/1538-7445.am2022-741.
Pełny tekst źródłaFu, Kai, Dennis D. Weisenburger, William W. L. Choi, Kyle D. Perry, Lynette M. Smith, Xinlan Shi, Christine P. Hans i in. "Addition of Rituximab to Standard Chemotherapy Improves the Survival of Both the Germinal Center B-Cell–Like and Non–Germinal Center B-Cell–Like Subtypes of Diffuse Large B-Cell Lymphoma". Journal of Clinical Oncology 26, nr 28 (1.10.2008): 4587–94. http://dx.doi.org/10.1200/jco.2007.15.9277.
Pełny tekst źródłaCao, Yabing, Ying Huang, Sheng Ye i Tongyu Lin. "Prognostic impact of immunohistochemically defined germinal center B-cell and nongerminal center B-cell subtypes of diffuse large B-cell lymphoma in rituximab era." Journal of Clinical Oncology 30, nr 15_suppl (20.05.2012): e18517-e18517. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e18517.
Pełny tekst źródłaHuang, Ying, Sheng Ye, Yabing Cao, Zhiming Li, Jiajia Huang, He Huang, Muyan Cai, Rongzhen Luo i Tongyu Lin. "Outcome of R-CHOP or CHOP Regimen for Germinal Center and Nongerminal Center Subtypes of Diffuse Large B-Cell Lymphoma of Chinese Patients". Scientific World Journal 2012 (2012): 1–7. http://dx.doi.org/10.1100/2012/897178.
Pełny tekst źródłaDunleavy, Kieron, Stefania Pittaluga, Myron S. Czuczman, Sandeep S. Dave, George Wright, Nicole Grant, Margaret Shovlin i in. "Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma". Blood 113, nr 24 (11.06.2009): 6069–76. http://dx.doi.org/10.1182/blood-2009-01-199679.
Pełny tekst źródłaWenzl, Kerstin, Bryce Manso, Yan W. Asmann, Matthew J. Maurer, Michelle Manske, Zhi-Zhang Yang, Susan L. Slager i in. "Whole-Exome Analysis Reveals Novel Somatic Genomic Alterations Associated with Cell of Origin in Diffuse Large B-Cell Lymphoma". Blood 128, nr 22 (2.12.2016): 2935. http://dx.doi.org/10.1182/blood.v128.22.2935.2935.
Pełny tekst źródłaDe Paepe, Pascale, Ruth Achten, Gregor Verhoef, Iwona Wlodarska, Michel Stul, Vera Vanhentenrijk, Marleen Praet i Chris De Wolf-Peeters. "Large Cleaved and Immunoblastic Lymphoma May Represent Two Distinct Clinicopathologic Entities Within the Group of Diffuse Large B-Cell Lymphomas". Journal of Clinical Oncology 23, nr 28 (1.10.2005): 7060–68. http://dx.doi.org/10.1200/jco.2005.15.503.
Pełny tekst źródłaDekker, Joseph D., Daechan Park, Arthur L. Shaffer, Holger Kohlhammer, Wei Deng, Bum-Kyu Lee, Gregory C. Ippolito i in. "Subtype-specific addiction of the activated B-cell subset of diffuse large B-cell lymphoma to FOXP1". Proceedings of the National Academy of Sciences 113, nr 5 (19.01.2016): E577—E586. http://dx.doi.org/10.1073/pnas.1524677113.
Pełny tekst źródłaWaller, Rosalie Griffin, Dennis P. Robinson, Anne J. Novak, Lisa M. Rimsza, Kerstin Wenzl, Rebecca L. King, Andrew L. Feldman i in. "Abstract 1181: Etiologic heterogeneity of genetic risk for DLBCL cell-of origin molecular subtypes". Cancer Research 83, nr 7_Supplement (4.04.2023): 1181. http://dx.doi.org/10.1158/1538-7445.am2023-1181.
Pełny tekst źródłaKim, Yu Ri, Soo-Jeong Kim, June-Won Cheong, Yundeok Kim, Ji Eun Jang, Jung Yeon Lee, Deok-Hwan Yang i in. "Upfront Autologous Stem Cell Transplantation Overcome the poor Prognosis of Non-Germinal Center Subtype of diffuse Large B-Cell Lymphoma in Patients with Advanced Stage and Elevated Serum Lactate Dehydrogenase". Blood 124, nr 21 (6.12.2014): 3998. http://dx.doi.org/10.1182/blood.v124.21.3998.3998.
Pełny tekst źródłaSoo, Joanne, David Matthew Kurtz, Florian Scherer, Alexander F. M. Craig, Michael C. Jin, Jason R. Westin, Davide Rossi i in. "Elucidation of distinct mutational patterns between diffuse large B cell lymphoma subtypes utilizing circulating tumor DNA." Journal of Clinical Oncology 35, nr 15_suppl (20.05.2017): 7538. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.7538.
Pełny tekst źródłaXu-Monette, Zijun Y., Ling Li, John C. Byrd, Kausar J. Jabbar, Ganiraju C. Manyam, Charlotte Maria de Winde, Michiel van den Brand i in. "Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma". Blood 128, nr 26 (29.12.2016): 3083–100. http://dx.doi.org/10.1182/blood-2016-05-715094.
Pełny tekst źródłaFoureau, David, Lawrence J. Druhan, Nury M. Steuerwald, Sarah A. Baxter, Omotayo O. Fasan, Belinda R. Avalos i Nilanjan Ghosh. "Cytokine Profiling of ABC-Subtype and GCB-Subtype Diffuse Large B Cell Lymphoma: Systemic Nfkb Activation and Impact on Myeloid-Derived Suppressor Cells Distribution". Blood 126, nr 23 (3.12.2015): 2666. http://dx.doi.org/10.1182/blood.v126.23.2666.2666.
Pełny tekst źródłaHavranek, Ondrej, Jingda Xu, Stefan Koehrer, Zhiqiang Wang, Justin M. Comer, Lisa Becker, Allen F. Yi i in. "Molecular Aspects of Tonic B-Cell Receptor Signaling in Diffuse Large B-Cell Lymphoma Provide Biomarkers and Targets for Specific Inhibition". Blood 128, nr 22 (2.12.2016): 779. http://dx.doi.org/10.1182/blood.v128.22.779.779.
Pełny tekst źródłaTakizawa, Jun, Sadao Aoki, Akihito Momoi, Toshiki Kitajima, Masutaka Higashimura, Naoya Nakamura i Yoshifusa Aizawa. "BCL6 Rearrangement Detected by FISH Analysis Is a Poor Prognostic Factor in the “Non-Germinal Center Phenotype” of Diffuse Large B-Cell Lymphoma." Blood 108, nr 11 (16.11.2006): 4620. http://dx.doi.org/10.1182/blood.v108.11.4620.4620.
Pełny tekst źródłaGupta, Mamta, Guangzhen Hu, Steven Offer, Matthew J. Maurer, Linda Wellik, Jing Jing Han, Ahmet Dogan, Robert B. Diasio i Thomas E. Witzig. "Expression but Not Promoter Hypermethylation of the Tyrosine Phosphatase PTPN6 Is Associated with Activated STAT3 and Inferior Prognosis in Diffuse Large B Cell Lymphoma Molecular Subtypes." Blood 120, nr 21 (16.11.2012): 2655. http://dx.doi.org/10.1182/blood.v120.21.2655.2655.
Pełny tekst źródłaZhao, Fengyi, Lei Zhang, Yan Qin, Ming-Zhe Han, Xiaohong Han, Shiyu Jiang i Yuankai Shi. "Characterization of Methylation Patterns in Diffuse Large B Cell Lymphoma By Genome-Wide Methylation Analysis". Blood 134, Supplement_1 (13.11.2019): 1243. http://dx.doi.org/10.1182/blood-2019-131656.
Pełny tekst źródłaAlcoceba, Miguel, Elena Sebastián, Ana Balanzategui, Luis Marín, Santiago Montes-Moreno, Teresa Flores, Noemí Puig i in. "Preferential Acquision of N-Glycosylation Sites in the VDJ Region in Germinal Center B-Cell-Like Difusse Large B-Cell Lymphoma". Blood 120, nr 21 (16.11.2012): 1589. http://dx.doi.org/10.1182/blood.v120.21.1589.1589.
Pełny tekst źródłaNowakowski, Grzegorz S., Betsy LaPlant, William R. Macon, Craig B. Reeder, James M. Foran, Garth D. Nelson, Carrie A. Thompson i in. "Lenalidomide Combined With R-CHOP Overcomes Negative Prognostic Impact of Non–Germinal Center B-Cell Phenotype in Newly Diagnosed Diffuse Large B-Cell Lymphoma: A Phase II Study". Journal of Clinical Oncology 33, nr 3 (20.01.2015): 251–57. http://dx.doi.org/10.1200/jco.2014.55.5714.
Pełny tekst źródłaGozgit, Joseph M., Youngchul Song, Scott Wardwell, Sara Nadworny, Yaoyu Ning i Victor M. Rivera. "Potent Preclinical Activity of Ponatinib in Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma (GCB-DLBCL) Models". Blood 126, nr 23 (3.12.2015): 4000. http://dx.doi.org/10.1182/blood.v126.23.4000.4000.
Pełny tekst źródłaZettl, Andreas, Silvia Bea, George Wright, Itziar Salaverria, Philipp Jehn, German Ott, Wing-Chung Chan i in. "Chromosomal Imbalances in Germinal Center B-Cell-Like and Activated B-Cell-Like Diffuse Large B-Cell Lymphoma Influence Gene Expression Signatures and Improve Gene Expression-Based Survival Prediction(the First Two Authors Contributed Equally to This Work)." Blood 104, nr 11 (16.11.2004): 415. http://dx.doi.org/10.1182/blood.v104.11.415.415.
Pełny tekst źródłaCao, Y., T. Lin, S. Wang, X. Fu, J. Xiao, J. Yi, H. Lin i Z. Guan. "A phase II study of R-CHOP in treatment of diffuse large B-cell lymphoma (DLBCL) subgroups". Journal of Clinical Oncology 24, nr 18_suppl (20.06.2006): 17540. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.17540.
Pełny tekst źródłaZhao, Peiqi, Huilai Zhang, Kai Fu, Xianhuo Wang, Lanfang Li, Zhengzi Qian, Lihua Qiu i Shiyong Zhou. "CD5 Expression Correlates with Inferior Survival and Enhances the Negative Effect of p53 Overexpression in Diffuse Large B Cell Lymphoma". Blood 134, Supplement_1 (13.11.2019): 4117. http://dx.doi.org/10.1182/blood-2019-127666.
Pełny tekst źródłaWang, Y. Lynn, Jiao Ma, Wei Xing, Pin Lu, Karen Dresser, Ailin Guo, Anjali Pandey, Pamela B. Conley, Hongbo Yu i Greg Coffey. "SYK and STAT3 Are Active in Diffuse Large B-Cell Lymphoma: Activity of Cerdulatinib, a Dual SYK/JAK Inhibitor". Blood 124, nr 21 (6.12.2014): 926. http://dx.doi.org/10.1182/blood.v124.21.926.926.
Pełny tekst źródłaFeng, Ru, Xiaolei Wei, Meng Xu, Fen Huang, Yongqiang Wei, Tong Zhao i B. Hilda Ye. "STAT3 Predicts Poor Outcome In Patients With Advanced Diffuse Large B Cell Lymphoma". Blood 122, nr 21 (15.11.2013): 5069. http://dx.doi.org/10.1182/blood.v122.21.5069.5069.
Pełny tekst źródłaQu, Jie, Matthew J. Maurer, James R. Cerhan, Anne J. Novak, Thomas M. Habermann, William R. Macon, Andrew L. Feldman i in. "Similar Phenotypes Demonstrated upon Initial Diagnosis and at Time of Recurrence in Relapsed DLBCL". Blood 128, nr 22 (2.12.2016): 5299. http://dx.doi.org/10.1182/blood.v128.22.5299.5299.
Pełny tekst źródłaEnnishi, Daisuke, Ali Bashashati, Saeed Saberi, Anja Mottok, Barbara Meissner, Merrill Boyle, Susana Ben-Neriah i in. "Frequent Genetic Alterations of PI3K-AKT Pathway and Their Clinical Significance in Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma". Blood 128, nr 22 (2.12.2016): 607. http://dx.doi.org/10.1182/blood.v128.22.607.607.
Pełny tekst źródłaPrakash, Gaurav, Atul Sharma, Vinod Raina, Lalit Kumar i Mehar C. Sharma. "Outcome in different molecular subtypes of diffuse large B-cell lymphoma: Indian experience." Journal of Clinical Oncology 30, nr 15_suppl (20.05.2012): e18518-e18518. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e18518.
Pełny tekst źródłaYunalda, Indah, Krisna Murt, Aida Farida, Ika Kartika i Erial Bahar. "Density of CD8 in Tumor Microenvironment of Diffuse Large B Cell Lymphoma Subtypes". Majalah Patologi Indonesia 30, nr 2 (1.05.2021): 227–33. http://dx.doi.org/10.55816/mpi.v30i2.466.
Pełny tekst źródłaTatterton, Dylan J., Benjamin Sale, Joel Allen, Maddy L. Newby, Giorgia Chiodin, Patrick J. Duriez, John Butler i in. "Oligomannose-Type Glycans in the Antigen Binding Site Identify Origin and Prognosis of Diffuse Large B Cell Lymphoma". Blood 142, Supplement 1 (28.11.2023): 428. http://dx.doi.org/10.1182/blood-2023-188721.
Pełny tekst źródłaFu, K., K. D. Perry, L. M. Smith, C. P. Hans, T. C. Greiner, W. C. Chan, D. D. Weisenburger i in. "Effect of addition of rituximab to CHOP on survival of patients in both the GCB and non-GCB subgroups of diffuse large B-cell lymphoma". Journal of Clinical Oncology 25, nr 18_suppl (20.06.2007): 8040. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.8040.
Pełny tekst źródła